Biotricity

Biotricity Current Liabilities

Delisted

The Current Liabilities of Biotricity (BTCY) as of Oct 31, 2026 is 20.64 M USD. In the previous year, Current Liabilities was 22.70 M USD — a change of -9.09% (lower).

Current Liabilities

20.64 MUSD

YoY

-9.09%

Last updated:

Current Liabilities of Biotricity is 2025 20.64 M USD. Current Liabilities of Biotricity was 2024 22.70 M USD. It decreases by -9.09% lower compared to the previous year.

The Biotricity Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
760,000.00 USD
Jan 1, 2019
2.27 M USD
Jan 1, 2020
3.80 M USD
Jan 1, 2021
10.49 M USD
Jan 1, 2022
4.87 M USD
Jan 1, 2023
11.16 M USD
Jan 1, 2024
22.70 M USD
Jan 1, 2025
20.64 M USD
The Biotricity Current Liabilities history
YEARCurrent LiabilitiesYoY
20.64 MUSD-9.09%
22.70 MUSD+103.40%
11.16 MUSD+129.16%
4.87 MUSD-53.57%
10.49 MUSD+176.05%
3.80 MUSD+67.40%
2.27 MUSD+198.68%
760,000.00USD-84.36%
4.86 MUSD+268.18%
1.32 MUSD+221.95%
410,000.00USD+127.78%
180,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biotricity Stock analysis

What does Biotricity do? Biotricity, Inc. generates revenue through its remote biometric monitoring solutions, primarily targeting healthcare providers and patients with chronic conditions. The company offers bioflux, an Electrocardiogram (ECG) monitoring system that enables physicians to diagnose cardiovascular diseases and coronary heart diseases, detect arrhythmias via ambulatory monitoring, and provide real-time remote mobile cardiac telemetry diagnostics. Additionally, Biotricity sells biolife, a health and lifestyle solution for individuals that monitors heart-rhythm, ECG, respiration, calories, temperature, and physical activity through a dedicated device. Healthcare institutions and patients seeking chronic condition management and lifestyle improvement are the primary buyers of these products. The firm's revenue streams are derived from the sale of bioflux systems to medical professionals for diagnostic and post-diagnostic use, while biolife targets individual consumers for personal health monitoring. Bioflux is utilized by physicians for real-time ECG data transmission and arrhythmia detection, and biolife is marketed directly to individuals for comprehensive health tracking. Both products are sold through direct sales channels to their respective target segments. Biotricity's business model relies on the dual focus of medical diagnostics and consumer health solutions. The company's products are designed to serve two distinct market segments: healthcare providers using bioflux for clinical diagnostics and patients using biolife for personal health management. The remote monitoring capabilities of both systems facilitate ongoing health data collection and analysis, supporting chronic disease management and lifestyle enhancement. Biotricity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotricity stock

Current Liabilities of Biotricity is 20.64 M USD in 2025.

Current Liabilities of Biotricity changed from 22.70 M USD to 20.64 M USD, representing a -9.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Biotricity since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Biotricity historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biotricity

All Key Metrics — Biotricity